About

About ImmuneOncia Therapeutics Inc ImmuneOncia is a clinical-stage biotech company focused on immuno-oncology established in 2016. ImmuneOncia is dedicated to delivering safe, effective, and novel immunotherapies to oncology patients worldwide. Its portfolio includes a variety of immune checkpoint antibodies such as PD-L1, CD47, LAG3 and Bi-specifics. ImmuneOncia is seeking partners for its immuno-oncology pipeline drugs as shown below. 1) IMC-002 (CD47 mAb) - Ph 1b trial for solid tumors ongoing; Superior safety and PK profile due to lack of RBC binding and less antigen sink; Open to Regional or Global (excl. China) collaboration 2) IMC-001 (PD-L1 mAb) – Ph 2 trial for Extranodal NK/T cell Lymphoma(ENKTL) completed and orphan drug designated (ODD); Ph 2 trial for TMB-H solid tumors ongoing; Open to Regional or Global collaboration 3) IMC-201 (CD47xPD-L1 bsAb) - Preliminary safety and efficacy data from in-vitro and/or in-vivo data; Open for Regional or Global collaboration